Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.40 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22601439 | 0.85 | TTK (0.44) | — | |
| SCHEMBL20224121 | 0.81 | HRH4 (0.56) | MEN1KMT2ASMN1; SMN2LMNAHSD17B10 | |
| SCHEMBL22601587 | 0.81 | HRH4 (0.51) | MEN1KMT2AALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL22601451 | 0.80 | HRH4 (0.54) | MEN1KMT2AALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL20224116 | 0.78 | KMT2A (0.47) | MEN1KMT2ADRD2DRD3TRPV6 | |
| SCHEMBL22601526 | 0.78 | CHRNA7 (0.47) | MEN1KMT2ADRD3ALDH1A1SMN1; SMN2 | |
| SCHEMBL22601438 | 0.78 | KDM4E (0.45) | MEN1KMT2AALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL20224125 | 0.77 | LMNA (0.45) | MEN1KMT2AALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL20224122 | 0.77 | ADRB2 (0.51) | ALDH1A1HRH4HTR7 | |
| SCHEMBL22601437 | 0.75 | LMNA (0.49) | MEN1KMT2ASMN1; SMN2LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200339530-A1 | UREA DERIVATIVES AS INHIBITORS OF ASK1 | HEPAGENE THERAPEUTICS, INC. (VG) | 2020-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339530-A1 | UREA DERIVATIVES AS INHIBITORS OF ASK1 | ATF1, ERN1, MAP3K1 | MEN1 3421/4885KMT2A 2727/4885DRD2 4831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.